AbbVie (NYSE:ABBV) Trading Down 0.7% - Here's What Happened

AbbVie Inc. (NYSE:ABBV - Get Free Report) shares fell 0.7% on Tuesday . The stock traded as low as $163.81 and last traded at $165.14. 994,935 shares traded hands during trading, a decline of 82% from the average session volume of 5,462,635 shares. The stock had previously closed at $166.28.

Analyst Upgrades and Downgrades

Several equities analysts have commented on ABBV shares. Barclays raised their target price on shares of AbbVie from $200.00 to $212.00 and gave the company an "overweight" rating in a report on Monday, October 7th. JPMorgan Chase & Co. decreased their price objective on shares of AbbVie from $210.00 to $200.00 and set an "overweight" rating on the stock in a research note on Wednesday, November 13th. William Blair upgraded AbbVie to a "strong-buy" rating in a research note on Friday, August 30th. Morgan Stanley decreased their price target on AbbVie from $231.00 to $224.00 and set an "overweight" rating on the stock in a research note on Tuesday, November 12th. Finally, Bank of America upped their price objective on AbbVie from $185.00 to $195.00 and gave the stock a "neutral" rating in a research report on Friday, October 18th. Three investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $203.37.

AbbVie Price Performance

The stock has a market capitalization of $294.41 billion, a price-to-earnings ratio of 57.34, a P/E/G ratio of 2.01 and a beta of 0.63. The company has a fifty day simple moving average of $191.44 and a 200 day simple moving average of $181.08. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.54 and a current ratio of 0.65.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Wednesday, October 30th. The company reported $3.00 EPS for the quarter, topping the consensus estimate of $2.92 by $0.08. The firm had revenue of $14.46 billion for the quarter, compared to the consensus estimate of $14.28 billion. AbbVie had a return on equity of 244.01% and a net margin of 9.22%. The business's quarterly revenue was up 3.8% compared to the same quarter last year. During the same period in the previous year, the business earned $2.95 EPS. Equities research analysts forecast that AbbVie Inc. will post 10.95 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be given a $1.64 dividend. The ex-dividend date of this dividend is Wednesday, January 15th. This is a positive change from AbbVie's previous quarterly dividend of $1.55. This represents a $6.56 annualized dividend and a dividend yield of 3.94%. AbbVie's dividend payout ratio (DPR) is 215.28%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Second Line Capital LLC bought a new position in AbbVie in the third quarter worth approximately $379,000. TCW Group Inc. boosted its holdings in AbbVie by 0.5% in the third quarter. TCW Group Inc. now owns 403,638 shares of the company's stock worth $79,710,000 after acquiring an additional 2,199 shares in the last quarter. Hohimer Wealth Management LLC boosted its holdings in AbbVie by 12.6% in the third quarter. Hohimer Wealth Management LLC now owns 1,432 shares of the company's stock worth $283,000 after acquiring an additional 160 shares in the last quarter. Fortem Financial Group LLC boosted its holdings in AbbVie by 19.1% in the third quarter. Fortem Financial Group LLC now owns 8,509 shares of the company's stock worth $1,680,000 after acquiring an additional 1,362 shares in the last quarter. Finally, Arete Wealth Advisors LLC bought a new position in AbbVie in the third quarter worth approximately $4,888,000. Institutional investors own 70.23% of the company's stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.